Clinical Trials Logo

Tolerability clinical trials

View clinical trials related to Tolerability.

Filter by:

NCT ID: NCT01348737 Completed - Healthy Volunteers Clinical Trials

Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers

Start date: June 2011
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety, tolerability and blood concentration of AZD3839 following oral administration of single doses in healthy men and women of non-childbearing potential

NCT ID: NCT01260025 Completed - Pharmacokinetics Clinical Trials

Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor

Start date: September 2009
Phase: Phase 1
Study type: Interventional

1. MTD and DLT of M2ES 2. Pharmacokinetics of M2ES

NCT ID: NCT01166698 Completed - Healthy Volunteers Clinical Trials

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

Start date: August 2010
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess safety and tolerability of AZD9819 following inhaled administration of single and multiple increasing doses, and to estimate the maximum dose that is tolerated in healthy people.

NCT ID: NCT01158755 Completed - Pharmacokinetics Clinical Trials

Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study

Start date: October 2010
Phase: Phase 2
Study type: Interventional

Tuberculous meningitis (TBM) is the most lethal form of tuberculosis infection, and is diagnosed in approximately 5-10% of TB patients. The incidence of TBM has increased considerably during the last decade, partly due to the HIV epidemic. Without treatment, virtually all patients with TB meningitis will die. With the current treatment regimens, TBM is fatal in approximately 30-50% of cases, and responsible for severe disability in a similar proportion of survivors. Worldwide, Indonesia the third highest case load of tuberculosis with an estimated 500,000 new patients / year. Representative data are lacking, but it is clear that TBM is a growing problem. For instance, in Hasan Sadikin Hospital, the top-referral hospital for West Java Province (population 40 million), Indonesia, 40-50 cases of TBM were treated yearly in the late 90's compared to approximately 100 in recent years. There is very little evidence for the current treatment regimen for TBM, which dates back to the late 60's. Therefore, there is an urgent need to evaluate intensified treatment of TBM in randomized trials. We hypothesize that higher dose rifampicin, moxifloxacin (possibly also at high dose), or both will improve outcome of TBM. To determine the experimental regimen(s) which should be compared with current regimen in phase 3 trials, we want to evaluate pharmacokinetic aspects and toxicity of candidate regimens in a phase 2 clinical trial in 60 patients with TBM in Indonesia.

NCT ID: NCT01154621 Completed - Healthy Clinical Trials

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The aim of this study is to examine the safety and tolerability of a single dose of AZD9742 in elderly individuals.

NCT ID: NCT01121302 Completed - Tolerability Clinical Trials

Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

Start date: May 2010
Phase: Phase 1
Study type: Interventional

1. The main purpose of this study is to assess the safety and tolerability of AZD5213 after single oral doses. 2. Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how the study drug enters and leaves your body and how your body acts on the study drug) of AZD5213 in your blood and urine. One group of subjects will be studied to see how food affects the pharmacokinetics (PK) of AZD5213 in the blood and urine. They will receive AZD5213 once after fasting overnight and then return to the clinic to receive AZD5213 after eating a high fat breakfast.

NCT ID: NCT01086813 Withdrawn - Pharmacokinetics Clinical Trials

Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043

AZD3043
Start date: March 2010
Phase: Phase 1
Study type: Interventional

Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after aSingle Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly(=65 years) Healthy Volunteers

NCT ID: NCT01023282 Completed - Parkinson's Disease Clinical Trials

Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.

NCT ID: NCT00967317 Not yet recruiting - Efficacy Clinical Trials

Phase III Open Study, Prospective, Multicenter, Randomized, Comparative to the Positive Control for Evaluating the Efficacy and Safety of Auris-Sedina in the Symptomatic Control of Otalgy in Patients With or Without Acute External Otitis.

E02OSMAS0108
Start date: December 2009
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and tolerability of Auris-Sedina in the symptomatic control of otalgy in patients with and without acute external otitis compared with use of Otosynalar®.

NCT ID: NCT00944268 Not yet recruiting - Anxiety Clinical Trials

Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety

E01ATCAL0308
Start date: September 2009
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety. Clinical study phase III, multicenter, prospective, open. Patients will be included in sufficient quantity to achieve the minimum number of 124 evaluable patients.